Skip to main content

Table 2 Seroprevalence of SARS-CoV-2 infection by age, sex, area of residence (location) and vaccination status, March – June 2021 (N = 7593)

From: SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021

   

Seroprevalence (95% confidence interval)

N

n

Crude % [95%CI]

Age-sex-location-weighteda % [95%CI]

Age-sex-location-weighted. Adjusted by test characteristicb % [95%CI]

Overall

7593

4884

64.3 [63.2–65.4]

61.8 [60.7–62.9]

65.5 [64.3–66.6]

Age group (years)

  < 10

937

445

47.5 [44.3–50.7]

47.2 [44–50.4]

50 [46.6–53.4]

 10–14

738

424

57.5 [53.9–61]

56 [52.8–59.2]

59.3 [55.9–62.7]

 15–19

483

321

66.5 [62.2–70.7]

66.1 [62.6–69.5]

70 [66.3–73.7]

 20–29

1266

830

65.6 [62.9–68.2]

63.4 [60.6–66.2]

67.2 [64.2–70.2]

 30–39

1640

1145

69.8 [67.6–72]

69.8 [66.8–72.9]

74 [70.8–77.3]

 40–49

1153

789

68.4 [65.7–71.1]

67.7 [63.9–71.5]

71.8 [67.7–75.8]

 50–59

767

518

67.5 [64.2–70.8]

65.7 [60.5–70.9]

69.7 [64.2–75.2]

 60–70

382

270

70.7 [66.1–75.2]

66.9 [64–69.8]

70.9 [67.8–74]

 70+

227

142

62.6 [56.3–68.9]

60.1 [57.5–62.7]

63.7 [61–66.4]

Sex

 Female

4164

2689

64.6 [63.1–66]

61.1 [59.5–62.6]

64.7 [63.1–66.3]

 Male

3429

2195

64 [62.4–65.6]

62.5 [61–64]

66.2 [64.6–67.8]

Location

 Rural

3593

2184

60.8 [59.2–62.4]

58.5 [57.2–59.9]

62.0 [60.6–63.5]

 Urban

4000

2700

67.5 [66.0–69.0]

67.3 [65.6–69]

71.3 [69.5–73.1]

Already vaccinated against COVID-19 (n = 6240)

 No

4924

3102

63.0 [61.6–64.3]

61.6 [59.1–63.0]

65.1 [63.7–67.4]

 Yes

1316

1102

83.7 [81.7–85.7]

81.7 [79.5–83.8]

86.5 [84.2–88.8]

  1. N: Sample size
  2. n: SARS-COV-2 positive subjects
  3. aWeighted on age, gender and location
  4. bWeighted and then adjusted according to the characteristics of the test